Foretinib

Research use only, not for human use.

Foretinib (XL880, GSK1363089, GSK089, EXEL-2880) is a potent, multikinase inhibitor that inhibits c-Met and VEGFR, also KIT, Flt-3, PDGFRβ, and Tie-2.

Foretinib (XL880, GSK1363089, GSK089, EXEL-2880) is a potent, multikinase inhibitor that inhibits c-Met and VEGFR, also KIT, Flt-3, PDGFRβ, and Tie-2; inhibits HGFR family tyrosine kinases with IC50 of 0.4 nM for Met and 3 nM for Ron, also inhibits KDR, Flt-1, and Flt-4 with IC50 of 0.9, 6.8, and 2.8 nM, respectively; exhibits modest activity against FGFR1 and EGFR, no activity against 50 serine/threonine kinases, including CDKs and PKC isoforms; inhibits cellular HGF-induced Met phosphorylation and VEGF-induced ERK phosphorylation and prevents both HGF-induced responses of tumor cells and HGF/VEGF-induced responses of endothelial cells; exhibits significant inhibition of tumor burden in animal model of lung metastasis.Lung Cancer Phase 2 Discontinued.

——

——

XL880 | GSK1363089 | GSK089 | EXEL-2880

Angiogenesis

c-Met/HGFR

Met|RON|Tie-2|VEGFR2?(KDR)|VEGFR3/FLT4|KDR|Flt-4|Flt-3

Cancer

Lung Cancer

849217-64-7

632.6537

C34H34F2N4O6

>98% (HPLC)

DMSO: ≥ 38 mg/mL

O=C(C1(C(NC2=CC=C(F)C=C2)=O)CC1)NC3=CC=C(OC4=CC=NC5=CC(OCCCN6CCOCC6)=C(OC)C=C45)C(F)=C3

1,1-Cyclopropanedicarboxamide, N-[3-fluoro-4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinolinyl]oxy]phenyl]-N'-(4-fluorophenyl)-

(-20℃)

With Ice Pack

≥ 2 years